文章：

血浆miR-92a水平下调对多发性骨髓瘤及相关疾病有临床影响

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders

原文发布日期：2012-01-20

DOI: 10.1038/bcj.2011.51

类型: Original Article

开放获取: 是

英文摘要：

Recent studies have demonstrated that one-third of known microRNAs (miRNAs) are stably detectable in plasma. Therefore, we assessed plasma miRNAs to investigate the dynamics of oncomir 17-92a, which is highly expressed in multiple myeloma (MM) patients. The plasma miR-92a level in symptomatic MM patients was significantly downregulated compared with normal subjects (P<0.0001), regardless of immunoglobulin subtypes or disease stage at diagnosis. In contrast, miR-92a levels in peripheral blood CD8+ or CD4+ cells from MM patients were lower than those of normal subjects, and the miR-92a levels of the cells tended to correlate with plasma miR-92a levels. The plasma miR-92a level in the complete remission group became normalized, whereas the partial response (PR) and very good PR groups did not reach the normal range. In smoldering MM, the plasma miR-92a level did not show a significant difference compared with normal subjects. Our findings suggest that measurement of the plasma miR-92a level in MM patients could be useful for initiation of chemotherapy and monitoring disease status, and the level may represent, in part, the T-cell immunity status of these patients.

摘要翻译： 

近期研究表明，已知微RNA（miRNA）中有三分之一可在血浆中稳定检出。因此，我们检测血浆miRNA，以研究在多发性骨髓瘤（MM）患者中高度表达的癌基因miR-17-92簇的动态变化。与正常对照相比，有症状MM患者的血浆miR-92a水平显著下调（P<0.0001），且不受诊断时免疫球蛋白亚型或疾病分期影响。相反，MM患者外周血CD8⁺或CD4⁺细胞中的miR-92a水平低于正常对照，且细胞miR-92a水平与血浆水平呈一定相关性。完全缓解组患者的血浆miR-92a水平恢复至正常范围，而部分缓解（PR）和非常好的PR组仍未达正常。冒烟型MM患者的血浆miR-92a水平与正常对照无显著差异。我们的研究提示，检测MM患者血浆miR-92a水平可用于指导化疗启动及监测疾病状态，且该水平在一定程度上可反映患者的T细胞免疫状况。

原文链接：

Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders